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There are four distinct DENV serotypes, and within
DENV4, there are five distinct genotypes. The impact
of genotypic diversity is not known, nor is it clear
whether infection with one DENV4 genotype results
in protective immunity against the other genotypes.
To measure the impact of DENV4 genetic diversity,
we generated an isogenic panel of viruses containing
the envelope protein from the different genotypes.
We characterized many properties of these viruses
and find that a small number of amino acids changes
within the envelope have disproportionate impacts
on virus biology. Additionally, we observe large dif-
ferences in the ability of DENV4 antibodies, immune
sera, and vaccine sera to neutralize the panel, sug-
gesting that DENV4 immunity might not be equally
protective against all DENV4s. Our results support
the monitoring of changing or emerging DENV geno-
types and their role in escaping pre-existing neutral-
izing antibodies in people who have been vaccinated
or exposed to natural DENV4 infections.
INTRODUCTION
Dengue virus (DENV) is a single-stranded positive sense RNA vi-
rus. It is estimated that over one-third of the world’s population is
at risk for DENV infection, resulting in almost 400 million infec-
tions annually (Bhatt et al., 2013). Infection with DENV can result
in a range of symptoms, from subclinical or mild disease, to se-
vere DENV hemorrhagic disease and shock syndrome (Halstead,
2015; Katzelnick et al., 2016). There are four genetically and anti-
genically distinct DENV serotypes (DENV1–DENV4), which co-
circulate around the world (Weaver and Vasilakis, 2009; Calisher
et al., 1989; Holmes and Twiddy, 2003). Infection with one sero-
type is thought to provide long-term protection against subse-
quent infection with the homologous serotype; however, individ-
uals are at risk for infection with the remaining three serotypes
(Coloma and Harris, 2015). However, there are rare instancesª 2018 The Author(s).
This is an open access article under the CC BY license (http://creativeof reinfection with the homologous serotype (Forshey et al.,
2016; Waggoner et al., 2016), suggesting that homotypic immu-
nity may fail to prevent infection under some conditions (Katzel-
nick et al., 2015).
The four DENV serotypes share approximately 80% homology
at an amino acid level across the entire coding region of the
genome (Fleith et al., 2016). The envelope glycoprotein is
roughly 70% conserved across DENV1–DENV4, containing fully
conserved regions with no variation (e.g., fusion loop), and other
regions containing highly divergent sequences (Rey et al., 2018).
The molecular and evolutionary drivers of variation between and
within serotypes remains uncertain (Bennett et al., 2010; Holmes
and Twiddy, 2003). As determined using phylogenetic analyses,
within each serotype, there are multiple genetically distinct
genotypes, which are more closely related to each other than
they are to the other serotypes (Weaver and Vasilakis, 2009).
DENV4 was first reported in the Philippines and Thailand in
1953, has since spread worldwide, and currently co-circulates
with DENV1–DENV3 (Messina et al., 2014). Within DENV4, there
are five distinct genotypes (I, II, III, IV, and V) with genotype II
being further divided into IIa and IIb (Figure 1) (Chen and Han,
2016). Genotypes I and II currently circulate in human popula-
tions throughout the world (Cao-Lormeau et al., 2011; Dash
et al., 2011; Fares et al., 2015; Klungthong et al., 2004).
Conversely, genotype III, IV, and V infections are relatively rare.
Genotype III has been detected sporadically in Asia between
1997 and 2015, and genotype V was primarily detected in India
in the 1960s, but has been detected as recently as 2009
(Klungthong et al., 2004; Zhao et al., 2010; Shihada et al.,
2017). Genotype IV is sylvatic, with only three known sequences
(Durbin et al., 2013; Rossi et al., 2012), and has not yet been
shown to spillover into humans, although rare cases of transient
spillover have been documented for DENV1–DENV3 (Teoh et al.,
2010; Vasilakis et al., 2008b).
In this manuscript, we used reverse genetics to generate a
panel of recombinant DENV4 viruses that contain an isogenic
backbone and differ only by the genotype sequence of the E pro-
tein. We used this panel of viruses to evaluate biological and
virological properties associated with the E protein including
its impact on neutralization using a well-characterized panel of
human monoclonal antibodies, convalescent DENV4 sera, andcommons.org/licenses/by/4.0/).
Figure 1. Phylogenetic Relationship of
DENV4 Genotypes
DENV4 envelope protein sequences were aligned
using neighbor-joining method with 100 replicates
based on the multiple sequence alignment.
Numbers in parentheses following virus species
names indicate the number of sequences repre-
sented at that tree position.vaccine sera from human volunteers. Our data reveal clear and
significant antigenic differences among the DENV4 genotypes,
which is critical for understanding immunity after natural DENV
infection and evaluating vaccine responses.
RESULTS
Design of DENV4 Isogenic Envelope Panel
Phylogenetic analyses of DENV4 identifies six groups desig-
nated as genotypes I, IIa, IIb, III, IV (sylvatic), and V (Figure 1).
As different isolates and genotypes of DENVs demonstrate var-
iable growth rates and foci morphology in cell culture, hampering
comparative studies of E protein variation, we used reverse ge-
netics to construct a panel of recombinant DENV4 viruses. Using
our previously described DENV4 molecular clone (genotype IIb)
(Gallichotte et al., 2015), we replaced the wild-type (WT) enve-
lope sequence with that from each of the other genotypes (Table
S1; Figure 2A). All other structural and non-structural proteins
were derived from WT DENV4, resulting in an isogenic panel of
viruses that only differ in the E gene sequence (Figure 2A).
Sequence analyses across the DENV4 genotype viruses reveal
significant amino acid variation in EDIII as well as residues
adjoining the hinge region between EDI and EDII (Figures 2B,
2C, and S1). When looking at the representative strain for each
genotype, some amino acids differ in only one virus (e.g., posi-
tion 132), whereas at other sites (e.g., position 351) the residues
are variable across multiple genotypes (Figures 2B and 2C).
DENV4 Viruses Differ in Growth Kinetics and Foci
Morphology
To recover recombinant viruses, full-length cDNAs were assem-
bled as previously described (Gallichotte et al., 2015; 2017).Viruses were isolated by electroporating
full-length infectious viral RNA into
C6/36 cells, and passaging cell-culture
supernatant once to produce infectious
stocks. When C6/36 insect cells were in-
fected in a multi-step viral growth curve
(MOI of 0.01), all viruses replicated with
similar kinetics and achieved similar
peak titers of about 107 ffu/mL after
4 days, with genotype IIa having slightly
lower titers at earlier time points (Fig-
ure 3A). Growth curves performed at a
higher MOI in C6/36 cells had similar
growth kinetics across the panel,
although viruses reached peak titers by
day 3 post-infection (Figure 3A). Therecombinant DENVs displayed more heterogeneous growth
kinetics on Vero cells following both low and high MOI infections
(Figure 3B). Genotype IIb viruses replicated most efficiently, and
genotype V was significantly attenuated in growth, with peak
titers 3 logs lower than that of the other genotypes (Figure 3B).
While genotype V was highly attenuated in Vero cells, it was
the only virus to cause complete syncytia in C6/36 cells (Fig-
ure S2). Although speculative, it is possible that this demon-
strates a virus adaptation for increased growth and spread in
insect cells and insects. Syncytia formation has been seen with
other strains of DENV (Pierro et al., 2006), but we did not observe
syncytia with any of the other DENV4 genotype viruses.
In addition to virus growth, we also compared viral foci
morphology (Figures 3C–3F). C6/36 foci were similar across
the entire panel (Figures 3C and 3D). Slightly more variation in
foci morphology and size was noted in Vero cells across the
panel, with genotype V producing the smallest foci; however,
all strains produced foci that were clearly defined and visible
(Figures 3E and 3F). The attenuated foci size of genotype V
was consistent with reduced replication in Vero cell growth
curves (Figure 3B).
DENV4 E Genotype Viruses Do Not Differ in
Thermostability
The large differences in viral replication of the DENV4 panel in
mammalian and insect cells (Figure 3) may be a result of different
temperature sensitivities, as studies have implicated envelope
sequences and virion stability (Lim et al., 2017). A thermostability
assay revealed that the DENV4 variants are similarly stable, with
little loss of infectivity after incubation at 28C and 37C; how-
ever, all viruses lost 1 log of infectivity after incubation at 40C
(Figure 4A). These results demonstrate that something other






























































Geno I V A I A M S L I T A N D A K T K T T L H H V A K T V R V I T F V T V D G
Geno IIa V A T A V L S I T A N D A K T K K A S H Y M A K A I R V I T F V I V D S
Geno IIb (WT) V A T A V S S I T A N D A K T K K A S H Y M A K A V R V V T L V T V N S
Geno IIb V A T A V S S I T A N D T K T K K A S H Y M A K A V R V V T L V T V N S
Geno III I A I A V S S I T A N D A E S E K A S H H M T R T V R V I T F V T V D S
Geno IV (sylvatic) V T I A V S S V A A N S T K T K G A S H Y M T K T I K M I I F I T A D S
Geno V V A I T V L S I T V K D A K T K K A S Q Y M T K A V R V I T F V T V D S
Residue
Domain I and II Domain IIIEnv
Number of viruses 








Figure 2. Design and Diversity of a Panel of DENV4 Genotypic Variants
(A) Sequences encoding the envelope protein from each genotype were placed into a genotype IIb (WT) infectious clone, resulting in recombinant viruses that are
entirely WT except for envelope protein, and sequence encoding envelope protein.
(B) Envelope protein amino acids positions that differ from WT (genotype IIb).
(C) Envelope protein amino acids that differ from WT are mapped on dimer based on number of genotypes differing at that position (PDB: 1OAN).than thermostability contributes to differences in the ability of the 
viruses to infect and replicate in mammalian and insect cells.
DENV4 E Variants Differ in Maturation Status, 
Enhanceability, and Glycosylation Pattern
As DENV maturation state may be heterogeneous in vitro, the re-
combinant panel allowed us to evaluate the role of E protein 
sequence on maturation status in an isogenic DENV4 backbone. 
During infection, DENV is assembled within the endoplasmic re-
ticulum as immature virions containing pre-membrane (prM) pro-
teins, which prevent fusion during viral egress. As DENV transits 
through the trans-Golgi network, pH change triggers cleavage of 
prM by the host protease furin. As the virus leaves the cell, 
cleaved pr dissociates, leaving fully mature viral particles. In 
cell culture, furin cleavage and pr dissociation are inefficient pro-
cesses and highly cell type dependent, leading to heterogonous 
population of differentially mature viruses, containing different 
amounts of uncleaved pr peptide (Pierson and Diamond, 
2012). As maturation status can influence infectivity and anti-
body neutralization (Mukherjee et al., 2014), we compared the 
maturation status across the DENV4 panel using immunoblotting 
and ELISAs (Figures 4B and 4C).
Immunoblotting revealed that the levels of pr protein varied 
across the panel, with genotype I and III being the least mature 
(most pr present) and genotypes IV and V being the most mature 
(very little pr protein detected) (Figure 4B). To corroborate these 
findings using a different assay, ELISA binding assays were per-
formed, by capturing DENV4 viruses with cross-reactive mono-
clonal antibodies (mAbs) 4G2 (anti-E) and 2H2 (anti-pr), then 
probing with a pr-specific antibody (1E16) (Smith et al., 2015). 
These studies also demonstrated that there are differing 
levels of pr protein across the panel (Figure 4C). Consistent 
with immunoblotting, genotype III was highly immature, whereasgenotype V was the most mature. As the DENV4 variant panel
contains differing amounts of pr protein (Figures 4B and 4C),
we sought to determine whether the viruses could be enhanced
by a non-neutralizing, pr-specific mAb (Smith et al., 2015). An
antibody-dependent enhancement (ADE) assay revealed that
despite differing levels of pr present on viruses, all viruses are
similarly enhanced, although the concentration of antibody
needed to achieve peak enhancement and the level of enhance-
ment do vary across the viruses (Figure 4D).
The furin cleavage site (located in prM protein) was not altered
across the panel, suggesting that the E protein sequence can
impact virus maturation (Pierson and Diamond, 2012). At a
neutral pH of the released virus, the pr protein sits over the
fusion-loop and is predicted to interact with seven amino acids
in EDII (Figures 4E and 4F); however, at low pH, during process-
ing of the virion, pr can make additional contacts across the en-
velope dimer. Under either condition, none of these amino acids
were altered in the panel, suggesting that other residues may
function to stabilize pr. Interestingly, there is little variability
within the paired pr protein sequences of the variant panel
(Figure S3).
Immunoblotting also revealed that the envelope protein of
genotype V is slightly smaller than that of the other genotypes
(Figure 4B). The DENV envelope protein contains two glycosyl-
ation sites, one in EDII (Asn-67) and one in EDI (Asn-153) (Fig-
ure 4E). Analysis of the glycosylation site sequences across
the panel revealed that a single amino acid change at residue
153 in genotype V disrupts the N-X-T/S glycosylation motif
(Figure 4G), resulting in a smaller molecular weight envelope
protein (Figure 4B). When looking at all genotype V viruses
used in our phylogenetic tree (Figure 1; Table S2), 87.5% have
amino acid variability that disrupts the Asn-153 glycosylation
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Figure 3. DENV4 Genotype Viruses Differ in Growth and Foci Morphology
(A and B) Viruses were analyzed for their ability to replicate in (A) C6/36 and (B) Vero cells at multiplicities of infection (MOI) of either 0.01 or 0.5 (mean ± SD of
biological triplicates).
(C–F) Viral foci were immunostained on both (C) C6/36 and (E) Vero cells, and average foci area for (D) C6/36 and (F) Vero cells were calculated using CTL
ImmunoSpot analyzer software (mean ± SD of biological triplicates).to the genotype V strain selected within our panel, but appears
to be conserved across most genotype V viruses. DENV enve-
lope glycosylation can be important for binding to host cell re-
ceptors, determining infectivity in different hosts, and binding
and neutralization by antibodies (Pokidysheva et al., 2006;
Mondotte et al., 2007; Rouvinski et al., 2015). Therefore, geno-
type V’s conserved lack of the second glycosylation site might
impact the virus’s ability to efficiently infect and be transmitted
between vertebrate and invertebrate hosts, and be the result of
adaptation to a different cellular or host tropism (Bryant et al.,
2007; Lee et al., 2010). Additionally, the lack of this glycosylation
site might contribute to the genotype V C6/36 syncytia pheno-
type (Figure S2). Genetic alteration of glycosylation and pr pro-
tein sequences, and generation of fully mature and fully imma-
ture virus preparations would allow one to determine the role
of glycosylation and maturation status on many aspects of virus
biology. Glycosylation status and large differences in viral matu-
ration state have previously been shown to impact antibody
binding and neutralization (Mukherjee et al., 2014); therefore,
the binding and neutralization differences we see within this
panel might be partially attributable to the variation in glycosyl-
ation and maturation.Binding of Serotype-Specific and Cross-Reactive mAbs
to DENV4 E Genotype Variants
We next measured the binding of a panel of well-characterized
DENV4 serotype-specific and DENV cross-reactive mAbs to
our DENV4 viruses by ELISA (Figure 5). DENV4 serotype-specific
antibodies D4-126 and D4-131 recognize partially overlapping
epitopes that have not been fully defined in the EDI/II hinge
region (Figures S4A and S4B) (Nivarthi et al., 2017). All DENV4
genotypes bound similarly to D4-126 and D4-131 (Figure 5A).
mAb D4-141, which recognizes an EDIII epitope (Figure S4C),
also bound all viruses similarly, despite large amount of variation
in EDIII across the panel (Figure 5A). The non-human primate
mAb 5H2, which binds to a well-defined epitope on EDI,
displayed highly variable binding across the panel (Figure 5A).
Two amino acids (162 and 174) predicted to be 5H2 contact res-
idues were variable across the DENV4 panel (Figure S4A) (Cock-
burn et al., 2012). Genotype III did not bind 5H2 and contains an
amino acid polymorphism at position 174, suggesting that this
position is essential for 5H2 binding.
The cross-reactive human mAbs C10 and B7 recognize qua-
ternary envelope dimer epitopes (EDEs) that span across the
























































































Asn-67 Asn-153 Virus 67 68 69 153 154 155
Geno I N I T N D T
Geno IIa N I T N D T
Geno IIb (WT) N I T N D T
Geno IIb N I T N D T
Geno III N I T N D T
Geno IV (sylvatic) N I T N S T
Geno V N I T K D T
Virus 64 66 83 84 103 248 249
Geno I S S K W N Q D
Geno IIa S S K W N Q D
Geno IIb (WT) S S K W N Q D
Geno IIb S S K W N Q D
Geno III S S K W N Q D
Geno IV (sylvatic) S S K W N Q D










Figure 4. DENV4 Genotype Viruses Differ in Thermostability, Maturation, and Glycosylation Status
(A) DENV4 viruses were evaluated for their thermostability at 28C, 37C, and 40C (mean ± SD of biological triplicates). Relative infectivity is calculated as
(ffu/mLtest temperature / ffu/mL4C) 3 100.
(B) Viruses were immunoblotted for envelope (E) and precursor (prM) protein present in viral stocks (representative image).
(C) Binding assay using pr-specific mAb 1E16 to detect amount of pr protein present in virus stocks (mean ± SD of biological triplicates).
(D) Antibody-dependent enhancement (ADE) assay was performed with DENV4 virus panel and anti-pr mAb 1E16 in U937 cells (mean ± SD of biological
duplicates).
(E) DENV envelope dimer showing location of putative pr interacting residues (navy) and glycosylation sites (yellow) (PDB: 1OAN).
(F) Envelope and putative pr interacting sites (via side-chain interactions) are listed for each genotype.
(G) Amino acid sequences of glycosylation sites 67 and 153 for each genotype. Genotype V lysine at amino acid position 153 (highlighted in red) disrupts
glycosylation motif (N-X-T/S).monomer (Figures S4A and S4B) (Rouvinski et al., 2015). These 
mAbs bind all four DENV serotypes, reflecting the highly 
conserved nature of the epitope across the DENV E protein. 
Consequently, it was not surprising that C10 and B7 bound all 
genotypes within the DENV4 panel with similar efficiencies (Fig-
ure 5B), as the differences between genotypes are smaller than 
those between serotypes. Binding of B7, however, is dependent 
on the presence of a glycan at position 153 in EDI (Rouvinski 
et al., 2015). The DENV4 genotype V virus in this panel, which 
lacked this glycosylation site (Figure 4E), failed to bind to the 
B7 antibody (Figure 5B).
Neutralization of DENV4 E Genotype Variants by 
Serotype-Specific and Cross-Reactive mAbs
Next, we evaluated the ability of DENV4 serotype-specific and 
cross-reactive mAbs to neutralize the DENV4 panel in a Verocell focus reduction neutralization test (FRNT), and a flow cy-
tometry-based neutralization assay with U937 cells expressing
DC-SIGN, a known DENV attachment factor (Figures 6A, 6B,
andS5).We observed a 1- to 2-log difference in antibody neutral-
ization titers of the DENV4 serotype-specific antibodies against
the DENV4 panel. Importantly, some mAbs were not able to
neutralize select genotypes even at the highest concentrations
tested, despite robust binding (e.g., D4-126 and genotype III)
(Figures 5A, 6A, and 6B). Other mAbs have similar neutralization
titers despite lower levels of binding (e.g., 5H2 and genotype V).
These results reveal that, for each mAb and virus, the amount
of mAb sufficient to bind and/or neutralize varies significantly.
Consonant with the binding results, EDE mAbs C10 and B7
potently neutralize all viruses similarly (Figures 6A and 6B), with
the exception of B7 and genotype V, due to its missing glycosyl-
ation site. The C10 and B7 epitopes are highly conserved across












































































DENV4 Serotype-Specific MAbs Cross-Reactive MAbs
Geno I Geno IIa Geno IIb (WT) Geno IIb Geno III Geno IV (sylvatic) Geno V
A B
Figure 5. mAbs Differentially Bind DENV4 Genotype Viruses
(A and B) DENV4 serotype-specific antibodies D4-126, D4-131, D4-141, and 5H2 (A) and DENV cross-reactive antibodies C10 and B7 (B) were evaluated for their
ability to bind each virus at a range of antibody concentrations using ELISAs (mean ± SD of technical duplicates).the DENV4 panel, likely explaining the robust and consistent
neutralizing titers (Figures S4A and S4B). Additionally, the
range of neutralization titers is smaller for cross-reactive
mAbs compared to serotype-specific mAbs, suggesting that
the more cross-reactive an antibody is (i.e., the more serotypes
it recognizes), the less genotypic diversity matters.
TheNeutralization of DENV4 EGenotype Variant Viruses
by Human Sera from Natural Infection and Vaccination
Convalescent immune sera from people who have recovered
from primary DENV4 infections contain strongly neutralizing
serotype-specific and weakly neutralizing cross-reactive anti-
bodies. We performed neutralization assays with DENV4 conva-
lescent immune sera to measure the breadth of neutralization
across different DENV4 E variant genotypes (Figures 7A
and S6A). While the absolute neutralization titers vary across
samples by 1–2 logs, all DENV4 immune sera were able to
neutralize all genotypes (Figure 7A). While this suggests that nat-
ural infection with any DENV4 genotype elicits antibodies that
are neutralizing against other genotypes as well, individuals
who have weaker responses may be vulnerable to reinfection
due to genotype variation.
Individuals who received a genotype II DENV4 monovalent
vaccine developed neutralizing antibodies (Figures 7B and
S6B). As seen with natural isolates (Durbin et al., 2013), we
also observed a larger spread in neutralization titers with the
monovalent vaccine immune sera (>2 logs) compared to the
natural infection sera. Additionally, for some vaccine sera,
neutralizing antibodies were undetectable against some geno-types, despite robust neutralization of other strains (e.g., sample
68 does not neutralize genotype IV or V, but potently neutralizes
genotype II viruses). Among the currently circulating geno-
type I, II, and III viruses, vaccine-matched genotype II viruses
were most potently neutralized. To determine whether the differ-
ential genotype neutralization is driven by serotype-specific or
cross-reactive antibodies, we used depletion techniques to spe-
cifically remove cross-reactive antibodies (de Alwis et al., 2012)
(Figures 7C, 7D, and S6C–S6E). We find that removing cross-
reactive antibodies minimally alters neutralization titers, sug-
gesting that the majority of total neutralization comes from sero-
type-specific antibodies, and that the differences in titers across
DENV4 genotypes are primarily driven by DENV4 serotype-spe-
cific antibodies as well.
We next looked at theDENV4genotypic neutralizing breadth of
individuals that received a tetravalent DENV vaccine. As tetrava-
lent vaccination can result in both DENV4 serotype-specific anti-
bodies, and strongly neutralizing cross-reactive antibodies,
depletion techniques were again used to determine the contribu-
tion of each population of antibodies to total neutralization.
Control depleted sera, containing both serotype-specific and
cross-reactive antibodies, differentially neutralized the DENV4
variants, with vaccine-matched genotype II viruses neutralized
on average 3- to 20-foldmore efficiently than theother genotypes
(Figures 7E and S7A). In addition, some sera failed to neutralize
currently circulating genotype I or III variants. When we removed
DENV serotype cross-reactive antibodies, we observed only a
small reduction in neutralization titers, indicating that the vac-







































MAb Focus Reduction Neutralization
Cross-ReactiveSerotype-Specific
Geno I Geno IIa Geno IIb (WT) Geno IIb Geno III Geno IV (sylvatic) Geno V
BA
Figure 6. DENV4 Genotypic Variants Are Differentially Neutralized by Monoclonal Antibodies
(A and B) DENV4 serotype-specific antibodies D4-126, D4-131, D4-141, and 5H2 and DENV cross-reactive antibodies C10 and B7 were evaluated for their ability
to neutralize DENV4 genotype viruses in (A) Vero cell focus reduction neutralization test (FRNT) and (B) flow cytometry-based neutralization assay (Neut) (mean ±
SD of technical duplicates). The y-axes represent the concentration of antibody required to neutralize 50% of infectious virus. The dashed line represents assay
limit of detection.(Figures 7F and S7B). Importantly, after removing cross-reactive 
antibodies, we see a similar spread in titers across the panel, sug-
gesting that DENV4 serotype-specific antibodies are driving 
the differential genotypic neutralization. When all DENV cross-
reactive and serotype-specific antibodies were depleted, we 
completely lost neutralization against all viruses (Figure S7C).
DISCUSSION
DENV is the most significant arthropod-borne virus, causing sig-
nificant morbidity and mortality worldwide. Sanofi-Pasteur’s 
tetravalent DENV vaccine, Dengvaxia, has been marketed and 
used in human populations, and there are two additional com-
mercial tetravalent vaccine candidates under evaluation in 
phase III human trials, including the NIH tetravalent DENV vac-
cine. Recent results with Dengvaxia demonstrate high vaccine ef-
ficacy in people who were dengue immune prior to vaccination 
(81.9%), and much poorer efficacy in people who were naive 
before vaccination (52.5%) (Hadinegoro et al., 2015). Moreover, 
naive individuals who received the vaccine appear to be at 
greater risk of developing severe disease, when exposed to a nat-
ural DENV infection approximately 24 months or more following 
the last dose of vaccine. As a result, Dengvaxia is currently rec-
ommended only for use in people who have been primed by nat-
ural DENV infections (Sridhar et al., 2018). Dengvaxia stimulated 
high levels of DENV4 serotype-specific neutralizing antibodies 
(Henein et al., 2017), and overall vaccine efficacy was highest 
against DENV4. However, in subjects who experienced DENV4 
breakthrough infections, molecular analyses indicated that 
the vaccine had a greater efficacy against vaccine-matched 
DENV4 genotype II than the co-circulating genotype I virus (Ra-
baa et al., 2017). These data underscore the need for developing 
viruses and reagents that capture intra-serotype genetic variation 
when evaluating vaccine immune responses and identifying 
potential antibody-based correlates of protective immunity.The existence of phylogenetically and antigenically distinct
DENV1–DENV4 serotypes is well accepted in the literature
(Holmes and Twiddy, 2003); however, the role of genetic diver-
sity across genotypes is less well studied. Many common
laboratory DENV strains have either been heavily cell culture
adapted and/or differ in sequence from contemporary circulating
strains (Dowd et al., 2015; Katzelnick et al., 2015, 2017). Addi-
tionally, some laboratory, and importantly, vaccine strains, are
composed of DENV genotypes that are likely extinct and, conse-
quently, do not circulate in human populations (Katzelnick et al.,
2017). While CD8+ T cells, CD4+ T cells, and other mechanisms
of cellular immunity are correlated with DENV protective immu-
nity (Mathew and Rothman, 2008), and antibodies against
DENV NS1 may also alter disease severity (Hertz et al., 2017),
neutralizing antibodies represent the best correlate of protection
to date (Katzelnick et al., 2016; Buddhari et al., 2014).
Natural DENV infection is thought to provide lifelong protec-
tion against symptomatic reinfection with that serotype (Katzel-
nick et al., 2016; Buddhari et al., 2014); however, it is unknown
whether individuals are protected with the same efficacy against
all genotypes within the serotype. There are reports of rare,
typically asymptomatic, homotypic reinfection in people in
Nicaragua and Peru (Forshey et al., 2016; Waggoner et al.,
2016), which is potentially driven by genotypic differences be-
tween the primary and secondary infecting viruses. Some
studies have evaluated the breadth of antibody neutralization
against different genotypes elicited by natural infection or vacci-
nation (Blaney et al., 2005; Durbin et al., 2013; Katzelnick et al.,
2015; Messer et al., 2012; Vasilakis et al., 2008a). While most in-
dividuals exposed to natural infections or vaccines neutralized
multiple genotypes within each serotype, absolute levels of
neutralizing antibodies vary depending on the individual and
the DENV genotypes used. Indeed, even in the current study,
we noted that most individuals exposed to natural infections







Figure 7. DENV4 Polyclonal Immune Sera Have a Range of Neutralization Titers against DENV4 Variants Driven by Serotype-Specific
Antibodies
(A and B) Using Vero cell focus reduction neutralization test (FRNT), (A) pooled polyclonal immune sera fromDENV4-infected non-human primates (NHPs) or from
naturally infected individuals, or from (B) individuals who received the NIH DENV4 monovalent vaccine were evaluated for their ability to neutralize DENV4
genotype viruses.
(C–F) DENV4 natural infection sera (C), DENV4 monovalent vaccine sera (D), and NIH DENV tetravalent vaccine sera were control depleted with BSA (E), or
depleted of cross-reactive antibodies (F) and evaluated for their ability to neutralize DENV4 genotype viruses. The y axis represents the dilution factor of immune
sera required to neutralize 50% of infectious virus (mean ± SD of technical duplicates). The dashed line represents one-half the assay limit of detection.prevalent DENV4 genotypes, but the levels of neutralizing anti-
body varied considerably by genotype. In 2008, theWorld Health
Organization (WHO) noted that there is little evidence of anti-
genic drift within DENV serotypes that might lead to resistance
of certain strains to post-vaccination neutralization, yet they
advised that laboratories consider inclusion of multiple virus
strains, including laboratory prototype strains and recent clinical
isolates when performing neutralization assays (Roehrig et al.,
2008). Our results demonstrate the value of including different
DENV genotypes when evaluating vaccine responses.
Using reverse genetics, we developed an isogenic panel of
DENV4 recombinant viruses that only differ in their E glycopro-
tein, which was derived from different genotypes. We recon-
structed clinically relevant isolates with E protein genes derived
from clinical specimens or low passage history in culture. Our
data demonstrate that DENV4 E protein genotypic diversity
can impact many aspects of the virus’s cell biology including
growth in cells, glycosylation, syncytial formation, and matura-
tion. Additionally, as all the viruses can be enhanced, it highlightsthe importance of determining the impact of DENV genetic vari-
ation on disease enhancement after infection and vaccination.
The chimeric DENV4 virus panel described here is a powerful
tool for initial assessment of the impact of DENV E genotypic
variation on virus biology and humoral immunity. As we selected
one representative envelope sequence per genotype and utilized
a recombinant approach, the viruses here do not capture all
E protein sequence diversity within each genotype and some
will never actually be encountered by vaccine recipients. Hence,
it will be important to evaluate more contemporary DENV4 geno-
type I, II, and III strains in future studies, including the use of both
natural and recombinantly derived isolates. In agreement with
our findings, we note that another study using WT strains of
endemic and sylvatic DENV4 viruses demonstrated better
neutralization of vaccine-matched endemic genotype II viruses
compared to sylvatic viruses using sera fromDENV4monovalent
vaccine recipients (Durbin et al., 2013).
Our results demonstrate that infection or vaccination with a
single DENV4 genotype stimulates variable levels of neutralizing
antibodies to different genotypes. Currently, there are insuffi-
cient data to correlate levels of neutralizing antibodies to protec-
tion from DENV disease. Moreover, other immune mechanisms
involving T cells, NS1 immunity, and B cell memory may also
reduce or eliminate clinical disease (Mathew and Rothman,
2008). However, it is worth noting that the licensed tetravalent
DENV vaccine (Dengvaxia) had higher vaccine efficacy against
vaccine-matched DENV4 genotype II (83%) viruses compared
to co-circulating DENV4 genotype I viruses (47%) (Rabaa et al.,
2017). We propose that targeted surveillance of changing or
emerging DENV genotypes following vaccination will be valuable
in assessing the influence of DENV genotype on the frequency of
repeat infections and overall vaccine effectiveness.
EXPERIMENTAL PROCEDURES
Phylogenetic Tree
The tree was constructed in Geneious R11 using the neighbor-joining method 
(Jukes–Cantor genetic distance) with 100 replicates based on the multiple 
sequence alignment. The radial phylogram was visualized and rendered for 
publication using CLC Sequence Viewer 7 and Adobe Illustrator CC 2017.
Virus Construction
Chimeric recombinant DENV4 viruses were constructed as described before 
(Gallichotte et al., 2015, 2017). Briefly, DNA encoding isogenic envelope protein 
sequences was introduced into a quadripartite DENV4 infectious clone system 
using synthetically derived genes and recombinant DNA approaches. Plasmid 
DNA was digested and ligated together, and viral full-length genomic RNA was 
generated using T7 RNA polymerase. Infectious genome-length capped viral 
RNA transcripts were electroporated into C6/36 cells, and supernatant was 
harvested and passaged onto C6/36 cells to make viral working stocks.
Cells
C6/36 cells (ATCC CRL-1660) were grown in minimum essential medium 
(MEM) at 32C. Vero cells (ATCC CCL-81) were grown in DMEM media, 
U937 and U937 cells stably expressing DC-SIGN (U937+DC-SIGN) were 
grown in RPMI medium 1640, and all were cultured at 37C. All media were 
supplemented with 5% fetal bovine serum (FBS), which was reduced to 2%
during DENV infection. All media were supplemented with 100 U/mL penicillin, 
100 mg/mL streptomycin, and 0.25 mg/mL amphotericin B. C6/36 and U937/
U937+DC-SIGN media were additionally supplemented with non-essential 
amino acids, and U937/U937+DC-SIGN media was further supplemented 
with L-glutamine and b-mercaptoethanol. All cells were incubated at 5% CO2.
Immune Sera
DENV4 immune non-human primate serum was obtained from BEI Resources 
(NR-41789). Human dengue immune sera were obtained from a previously 
described Dengue Traveler collection at the University of North Carolina. Vac-
cine sera were obtained from individuals who received a live-attenuated mono-
valent DENV4 or tetravalent vaccine 180 days post-vaccination, as developed 
by the NIH, and were provided by A.P.D. and S.S.W. All human sera samples 
were anonymized and obtained under Institutional Review Board approval.
Viral Titering and Immunostaining
Cells were plated 1 day prior to infection. Growth media was removed, and 
virus stocks were serially diluted 10-fold, added to cells, and incubated for 
1 hr at either 32C (C6/36) or 37C (Vero). After incubation, 1% methylcellulose 
in Opti-MEM (supplemented with 2% FBS, 100 U/mL penicillin, 100 mg/mL 
streptomycin, and 0.25 mg/mL amphotericin B) was overlaid, and cells were 
incubated for 3–4 days. Cells were washed with PBS and fixed with 80%
methanol. Cells were blocked in 5% non-fat dried milk and stained with anti-E 
(4G2) and anti-prM (2H2) mAbs and horseradish peroxidase (HRP)-labeled 
secondary antibody. Foci were developed using TrueBlue substrate, and viral 
foci were counted manually.Growth Curves
C6/36 or Vero cells were seeded in 24-well plates 1 day prior to infection.
Viruses were diluted to an MOI of either 0.01 or 0.5, added to cells, and incu-
bated for 1 hr at either 32C (C6/36) or 37C (Vero). Inoculum was removed,
cells were washed three times with PBS, and growth media were replaced.
Media were sampled daily, replaced with fresh media, and immediately frozen
at 80C. Samples were titered as described above.
Thermostability Assay
DENV4 viruses were diluted 1:10, then incubated at 4C, 28C, 37C, or 40C
for 1 hr, then immediately transferred to 4C for 15 min. Viruses were then
titered on Vero cells and immunostained as described above.
Immunoblotting
Virus stocks were diluted in PBS, mixed with sample buffer, and heated at
95C for 10 min. Samples were run on 4%–20% Protean TGX gels and
transferred to polyvinylidene difluoride (PVDF) membrane. Membranes were
blocked in 5% non-fat dried milk and probed with anti-E (4G2) and anti-prM
(1E16) mAbs. Membranes were washed and probed with secondary anti-
bodies labeled with HRP and developed using chemiluminescent substrate.
Membranes were visualized using a LI-COR C-DiGit Blot Scanner.
Enzyme-Linked Immunosorbent Binding Assay
Plates were coated with anti-E (4G2) and anti-prM (2H2) antibodies in carbon-
ate buffer overnight and blocked in 5% non-fat dried milk, and then virus an-
tigen was added. Primary antibody was diluted in blocking buffer and added
to plates for 1 hr at 37C. Alkaline-phosphate-labeled secondary antibody
was added and plates were incubated for 1 hr at 37C. Plates were developed
with p-nitrophenyl phosphate substrate and color changes were quantified
using Bio-Rad iMark Microplate Absorbance Reader.
ADE Assay
mAbs was diluted 5-fold and mixed with virus previously diluted to result in
15% infection in U937+DC-SIGN cells. Virus:mAb mixtures were incubated
at 37C for 45 min, and then added to 5 3 104 U937 cells and incubated at
37C for 2 hr. After incubation, cells were washed with growth media, and
then resuspended in fresh growth media. The cells were incubated for 20 hr
at 37C, washed in PBS, fixed in 10% phosphate-buffered formalin, and
then stained with anti-E mAb 4G2 directly conjugated to Alexa Fluor 488. Cells
were analyzed on a Guava easyCyte flow cytometer.
Neutralization Assays
FRNT was performed by seeding Vero cells 1 day prior to infection. mAbs or
immune sera were diluted 4-fold andmixedwith virus stocks previously diluted
to 40 ffu/well. Virus:Ab mixtures were incubated at 37C for 1 hr, and then
added to cells for 1 hr at 37C. After incubation, overlay media was added
and plates were incubated for 3 days. Cells were fixed and immunostained
as described as above. Flow cytometry-based neutralization assays were per-
formed as described above in ADE assays, except with U937+DC-SIGN cells.
Polyclonal Antibody Depletion Assay
Dynabeads were covalently bound to anti-E mAb 1M7 overnight at 37C.
Bead:mAb complex was blocked with 1% BSA in PBS at 37C, and then
washed with 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer. Beads
were incubated with BSA (control), purified DENV3 (cross-reactive depletion),
or a mix of DENV3 and DENV4 (full depletion) for 1 hr at 37C, and then
washed three times with PBS. Bead:mAb:DENV complex was fixed with 2%
paraformaldehyde in PBS for 20 min, and then washed four times with PBS.
DENV-specific antibodies were depleted from sera by incubating beads with
sera diluted 1:10 in PBS for 1 hr at 37C with end-over-end mixing for at least
two sequential rounds of depletions. Removal of DENV antibodies was
confirmed by ELISA.
Data Analysis and Software
All data were analyzed and graphed using GraphPad Prism v7.0a. Protein
structures were visualized usingMacPyMOL: PyMOL v1.7.6.2. Replicate infor-
mation is included in the figure legends.
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